<DOC>
	<DOCNO>NCT01424865</DOCNO>
	<brief_summary>RATIONALE : Studying sample tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . PURPOSE : This research trial study biomarkers predictor response trastuzumab sample patient breast cancer previously treat NSABP-B-31 trial .</brief_summary>
	<brief_title>Cancer Stem Cell Biomarkers Predictor Response Trastuzumab Samples From Patients With Breast Cancer Previously Treated NSABP-B-31 Trial</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine stem cellness identifies poor prognostic subgroup woman early-stage breast cancer uniformly treat either adjuvant doxorubicin hydrochloride &amp; cyclophosphamide follow paclitaxel ( `` control arm '' B31 ) , chemotherapy plus trastuzumab . Secondary - To conduct exploratory analysis assess , extent possible , co-localization stem cellness , determine ALDH1 positivity , HER2 identifies group patient previously consider HER2-negative cancer ( use classical definition ) benefit adjuvant trastuzumab . OUTLINE : Archived breast cancer stem cell sample terminally differentiated cell tissue sample analyze HER2 ALDH1 expression dual-staining quantitative immunofluorescence use Automated Quantitative Analysis ( AQUA ) , IHC , fluorescence situ hybridization ( FISH ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Tissue sample patient nodepositive breast cancer whose tumor overexpress HER2 Primary tumor sample negative HER2 use classically accept cutoff determine metastatic setting Treated adjuvant therapy comprise doxorubicin hydrochloride , cyclophosphamide , paclitaxel without trastuzumab NSABPB31 trial PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>